Actively Recruiting
Short-term Bactericidal Effect of Contezolid in MAC-PD
Led by Bin Cao · Updated on 2025-09-18
188
Participants Needed
3
Research Sites
127 weeks
Total Duration
On this page
Sponsors
B
Bin Cao
Lead Sponsor
B
Beijing Chest Hospital, Capital Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.
CONDITIONS
Official Title
Short-term Bactericidal Effect of Contezolid in MAC-PD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily agree to participate and sign informed consent.
- Age between 18 and 75 years, any gender.
- Confirmed diagnosis of MAC pulmonary disease with nodular bronchiectatic imaging features according to guidelines.
- No anti-MAC treatment within 3 months before screening.
- Premenopausal women not surgically sterile must use contraception during and 3 months after treatment, have a negative pregnancy test within 72 hours before enrollment, and not be breastfeeding.
- Male patients with partners of childbearing potential must use effective contraception during and 3 months after treatment.
- Meet organ function criteria within 1 week before enrollment, including specified blood counts, liver and kidney function, cardiac function, and stable blood glucose control.
You will not qualify if you...
- Allergy to any study drugs.
- Mixed infections with multiple mycobacteria, bacteria, fungi, or viruses including HIV.
- Congenital or acquired immunodeficiency, active pulmonary or other malignancies requiring treatment.
- History of solid organ transplantation.
- Currently on dialysis.
- Uncontrolled radiation pneumonitis, active interstitial lung disease, or significant pleural/pericardial effusion.
- Unstable serious systemic conditions including hypertensive crisis, unstable angina, severe heart failure, recent myocardial infarction, severe psychiatric disorders, severe liver or kidney dysfunction, or neurodegenerative diseases.
- Poor gastrointestinal function or malabsorption.
- Use of other investigational drugs within 4 weeks before study drug.
- Participation in another interventional trial unless observational or follow-up phase.
- Any clinical findings likely to interfere with study results or increase treatment risk as judged by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Active, Not Recruiting
2
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Jiangxi Provincial Chest Hospital
Nanchang, Jiangxi, China
Actively Recruiting
Research Team
S
Siwei Gu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here